Literature DB >> 12704070

The surgical bed after BCNU polymer wafer placement for recurrent glioma: serial assessment on CT and MR imaging.

Dima A Hammoud1, Clifford J Belden, Amy C Ho, Gerald J Dal Pan, Edward H Herskovits, Dana C Hilt, Henry Brem, Martin G Pomper.   

Abstract

OBJECTIVE: The objective of our study was to describe the CT and MR imaging appearances of the surgical bed in the brains of patients receiving biodegradable polymers impregnated with N, N'1, 3-Bis-(2-chloroethyl)-N-nitrosourea (BCNU) for recurrent glioma and to determine whether patients receiving placebos could be differentiated from those receiving BCNU based on the pattern and growth kinetics of tumor recurrence.
MATERIALS AND METHODS: The CT and MR images of 20 patients who underwent surgery for resection of recurrent high-grade gliomas and placement of intratumoral wafers (11 received BCNU polymer wafers, nine received control wafers) were analyzed for wafer appearance, volume of gas in the tumor bed, and volume of enhancement on serial scans.
RESULTS: Wafers appeared as linear hyperdense structures on CT and as linear low-signal-intensity structures on MR imaging and caused no significant enhancement. In the BCNU polymer group, gas volume was 4.0 +/- 3.4 cm(3) (mean +/- SD), whereas gas volume was 1.6 +/- 3.0 cm(3) for the placebo group (Mann-Whitney test, p = 0.03). A trend toward linear rather than exponential recurrent tumor growth was identified for the BCNU polymer group but not for the placebo group.
CONCLUSION: BCNU polymer wafers have a specific appearance on CT and MR imaging with which radiologists should be familiar: gas in the surgical bed is an expected transient finding, and tumor regrowth in patients receiving BCNU polymer wafers appeared to occur at a slower rate than in those receiving the placebo.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2003        PMID: 12704070     DOI: 10.2214/ajr.180.5.1801469

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: A pilot study.

Authors:  Rivka R Colen; Pascal O Zinn; Saman Hazany; Daniel Do-Dai; Julian K Wu; Kevin Yao; Jay J Zhu
Journal:  World J Radiol       Date:  2011-11-28

2.  Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Authors:  Stephan Ulmer; Klara Spalek; Arya Nabavi; Susan Schultka; H Maximillian Mehdorn; Santosh Kesari; Lutz Dörner
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

3.  Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.

Authors:  Shiro Ohue; Shohei Kohno; Akihiro Inoue; Daisuke Yamashita; Satoshi Suehiro; Toshimoto Seno; Yoshiaki Kumon; Keiichi Kikuchi; Takanori Ohnishi
Journal:  J Neurooncol       Date:  2015-09-18       Impact factor: 4.130

4.  Rapid regression of glioblastoma following carmustine wafer implantation: A case report.

Authors:  Junya Fukai; Hiroki Nishibayashi; Yuji Uematsu; Yonehiro Kanemura; Koji Fujita; Naoyuki Nakao
Journal:  Mol Clin Oncol       Date:  2016-05-10

5.  Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma.

Authors:  Andrew L Ko; Kathleen R Fink; Keith M Stelzer; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-11-20

Review 6.  The role of Gliadel wafers in the treatment of newly diagnosed GBM: a meta-analysis.

Authors:  Wei-kang Xing; Chuan Shao; Zhen-yu Qi; Chao Yang; Zhong Wang
Journal:  Drug Des Devel Ther       Date:  2015-06-29       Impact factor: 4.162

Review 7.  Polifeprosan 20, 3.85% carmustine slow release wafer in malignant glioma: patient selection and perspectives on a low-burden therapy.

Authors:  Lawrence Kleinberg
Journal:  Patient Prefer Adherence       Date:  2016-11-24       Impact factor: 2.711

8.  Early Postoperative Expansion of Parenchymal High-intensity Areas on T2-weighted Imaging Predicts Delayed Cerebral Edema Caused by Carmustine Wafer Implantation in Patients with High-grade Glioma.

Authors:  Yosuke Masuda; Eiichi Ishikawa; Tetsuya Yamamoto; Masahide Matsuda; Hiroyoshi Akutsu; Hidehiro Kohzuki; Kei Nakai; Emiko Okamoto; Shingo Takano; Tomohiko Masumoto; Akira Matsumura
Journal:  Magn Reson Med Sci       Date:  2015-12-28       Impact factor: 2.471

9.  Polifeprosan 20, 3.85% carmustine slow-release wafer in malignant glioma: evidence for role in era of standard adjuvant temozolomide.

Authors:  Lawrence Kleinberg
Journal:  Core Evid       Date:  2012-10-26

10.  In vitro Study of Serial Changes to Carmustine Wafers (Gliadel) with MR Imaging and Computed Tomography.

Authors:  Satoshi Doishita; Taro Shimono; Tetsuya Yoneda; Eiji Yamada; Taro Tsukamoto; Daichi Takemori; Daisuke Kimura; Hiroyuki Tatekawa; Shinichi Sakamoto; Yukio Miki
Journal:  Magn Reson Med Sci       Date:  2017-09-04       Impact factor: 2.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.